XOMA Corp
NASDAQ:XOMA

Watchlist Manager
XOMA Corp Logo
XOMA Corp
NASDAQ:XOMA
Watchlist
Price: 27.13 USD 8.04%
Market Cap: 319.6m USD
Have any thoughts about
XOMA Corp?
Write Note

XOMA Corp
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

XOMA Corp
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
XOMA Corp
NASDAQ:XOMA
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Effect of Foreign Exchange Rates
$4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Effect of Foreign Exchange Rates
$52m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Effect of Foreign Exchange Rates
$32.1m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
35%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Effect of Foreign Exchange Rates
$200k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

XOMA Corp
Glance View

Market Cap
318.9m USD
Industry
Biotechnology

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

XOMA Intrinsic Value
34.8 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

Back to Top